Dr. Esserman Discusses the I-SPY 2 Trial in Breast Cancer

Partner | Cancer Centers | <b>UCSF Helen Diller Family Comprehensive Cancer Center</b>

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

The I-SPY trials are neoadjuvant breast cancer trials designed for patients who are at a very high risk for early recurrence. Esserman explains that these trials aim to accelerate the pace of learning which agents are going to work for certain tumors. The I-SPY 2 trial (NCT01042379) is currently investigating neoadjuvant and personalized adaptive novel agents for the treatment of patients with breast cancer.

These trials are attempting to move the testing of new agents into the early-stage high-risk neoadjuvant setting. Esserman says that these trials test agents in the neoadjuvant setting, because that is where they can have the highest potential impact, or possibly cure patients.